On Tuesday, 04 March 2025, Alector Inc. (NASDAQ: ALEC) presented at the TD Cowen 45th Annual Healthcare Conference, outlining its strategic focus on developing disease-modifying drugs for ...

On Tuesday, 04 March 2025, Alector Inc. (NASDAQ: ALEC) presented at the TD Cowen 45th Annual Healthcare Conference, outlining its strategic focus on developing disease-modifying drugs for ...

Alector has a 52-week low of $1.38 and a 52-week high of $7.45. The firm has a market capitalization of $139.71 million, a price-to-earnings ratio of -0.83 and a beta of 0.61.

Shares of NASDAQ ALEC opened at $1.64 on Thursday. The company has a market capitalization of $162.50 million, a P/E ratio of -0.96 and a beta of 0.61. Alector has a 52-week low of $1.55 and a 52 ...

Alector ( NASDAQ:ALEC ) Full Year 2024 Results Key Financial Results Revenue: US$100.6m (up 3.6% from FY 2023). Net... Alector Inc (ALEC) reports significant growth in collaboration revenue and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker ...

Estimated General and Administrative Expenses (2025): Between $55-65 million. Alector Inc (NASDAQ:ALEC) is advancing two first-in-class late-stage clinical programs in collaboration with GSK, ...

Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...

SOUTH SAN FRANCISCO - Alector, Inc. (NASDAQ:ALEC) reported fourth quarter 2024 results that significantly exceeded analyst expectations, sending shares up 1.7% in after-hours trading. The late-stage ...